Measuring [18F]FDG uptake in breast cancer during chemotherapy: Comparison of analytical methods

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 30, Issue 5, 2003, Pages 674-681

  Krak, Nanda C ^a   Van der Hoeven, Jacobus J M ^b   Hoekstra, Otto S ^a   Twisk, Jos W R ^a   Van der Wall, Elsken ^a   Lammertsma, Adriaan A ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b AMSTELLAND HOSPITAL   (Netherlands)

Author keywords

Breast cancer; Chemotherapy; Positron emission tomography; Quantitative analysis; 18F FDG

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUORODEOXYGLUCOSE F 18; FLUOROURACIL; GLUCOSE;

ACCURACY; ADULT; ADVANCED CANCER; AGED; ANALYTIC METHOD; ARTICLE; BODY SURFACE; BODY WEIGHT; BONE METASTASIS; BREAST CANCER; CALCULATION; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; CORRELATION COEFFICIENT; DRUG UPTAKE; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; HUMAN; INTERMETHOD COMPARISON; LEAN BODY WEIGHT; METASTASIS; MULTIVARIATE ANALYSIS; POSITRON EMISSION TOMOGRAPHY;

EID: 0037907582     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-003-1127-z     Document Type: Article

References (56)

1. 18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr 1989; 13:1097-1098.
2. Wahl RL, Cody RL, Hutchins GD, et al. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analogue 2-[F-18]-fluoro-2-deoxy-Dglucose. Radiology 1991; 179:765-770.
3. Tse NY, Hoh CK, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg 1992; 216:27-34.
4. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol 1996; 14:1848-1857.
5. Noh DY, Yun IJ, Kim JS, et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg 1998; 22:223-227.
6. Avril N, Rose CA, Schelling M, et al. Breast imaging with positron emission tomography and fluorine-18 fluorodeoxyglucose: use and limitations. J Clin Oncol 2000; 18:3495-3502.
7. Czernin J. FDG-PET in breast cancer: a different view of its clinical usefulness [review]. Mol Imag Biol 2002; 4:35-45.
8. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer 1993; 71:3920-3925.
9. Adler LP, Crowe JP, al-Kaisi NK, et al. Evaluation of breast masses and axillary lymph nodes with [F-18] 2-deoxy-2-fluoro-D-glucose PET. Radiology 1993; 187:743-750.
10. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med 1996; 23:1588-1593.
11. Avril N, Dose J, Janicke F, Ziegler S, et al. Assessment of axillary lymph node involvement in breast cancer patients with positron emission tomography using radiolabeled 2-(fluorine18)-fluoro-2-deoxy-D-glucose. J Natl Cancer Inst 1996; 88: 1204-1209.
12. Smith IC, Ogston KN, Whitford P, et al. Staging of the axilla in breast cancer: accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-Dglucose. Ann Surg 1998; 228:220-227.
13. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol 1993; 11:2101-2111.
14. 18F]-fluoro-D-glucose uptake in locally advanced breast cancers. Eur J Surg Oncol 1995; 21:280-283.
15. Jansson T, Westlin JE, Ahlstrom H, et al. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol 1995; 13:1470-1477.
16. Bassa P, Kim EE, Inoue T, et al. Evaluation of preoperative chemotherapy using PET with fluorine-18-fluorodeoxyglucose in breast cancer. J Nucl Med 1996; 37:931-938.
17. Schelling M, Avril N, Nahrig J, et al. Positron emission tomography using [(18)F]fluorodeoxyglucose for monitoring primary chemotherapy in breast cancer. J Clin Oncol 2000; 18:1689-1695.
18. 99mTcsestamibi scintimammography for monitoring breast cancer response to neoadjuvant chemotherapy: a comparative study. Eur J Nucl Med 2001; 28:711-720.
19. 18F]-fluoro-2-deoxy-D-glucose in oncology. Part IIIa. Therapy response monitoring in breast cancer, lymphoma and gliomas [review]. J Cancer Res Clin Oncol 2001; 127:269-277.
20. 18F]-D-glucose. Cancer 1998; 82:2227-2234.
21. Smith IC, Welch AE, Hutcheon AW, et al. Positron emission tomography using [(18)F]-fluorodeoxy-D-glucose to predict the pathologic response of breast cancer to primary chemotherapy. J Clin Oncol 2000; 18:1676-1688.
22. 14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat. J Neurochem 1977; 28:897-916.
23. Phelps ME, Huang SC, Hoffman EJ. Tomographic measurement of local cerebral glucose metabolic rate in humans with (F-18)2-fluoro-2-deoxy-D-glucose: validation of method. Ann Neurol 1979; 6:371-388.
24. Huang SC, Phelps ME, Hoffman EJ. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol 1980; 238:E69-E82.
25. Keyes JWJ. SUV: standard uptake or silly useless value? J Nucl Med 1995; 36:1836-1839.
26. Hamberg LM, Hunter GJ, Alpert NM, et al. The dose uptake ratio as an index of glucose metabolism: useful parameter or oversimplification? J Nucl Med 1994; 35:1308-1312.
27. Huang SC. Anatomy of SUV. Nucl Med Biol 2000; 27:643-646.
28. Patlak CS, Blasberg RG, Fenstermacher JD. Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data. J Cereb Blood Flow Metab 1983; 3:1-7.
29. Hunter GJ, Hamberg LM, Alpert NM, Choi NC, Fischman AJ. Simplified measurement of deoxyglucose utilization rate. J Nucl Med 1996; 37:950-955.
30. Sadato N, Tsuchida T, Nakaumra S, et al. Non-invasive estimation of the net influx constant using the standardized uptake value for quantification of FDG uptake of tumours. Eur J Nucl Med 1998; 25:559-564.
31. Imran MB, Kubota K, Yamada S, et al. Lesion-to-background ratio in nonattenuation-corrected whole-body FDG PET images. J Nucl Med 1998; 39:1219-1223.
32. Wu HM, Hoh CK, Huang SC, Yao WJ, Phelps ME, Hawkins RA. Quantification of serial tumor glucose metabolism. J Nucl Med 1996; 37:506-513.
33. Wu HM, Huang SC, Choi Y, Hoh CK, Hawkins RA. A modeling method to improve quantitation of fluorodeoxyglucose uptake in heterogeneous tumor tissue. J Nucl Med 1995; 36: 297-306.
34. 18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. Eur J Cancer 1999; 35:1773-1782.
35. Brix G, Zaers J, Adam LE, et al. Performance evaluation of a whole-body PET scanner using the NEMA protocol. National Electrical Manufacturers Association. J Nucl Med 1997; 38:1614-1623.
36. Hudson HM, Larkin RS. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans Med Imaging 1994; 13:601-609.
37. Boellaard R, van Lingen A, Lammertsma AA. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J Nucl Med 2001; 42:808-817.
38. Hoekstra C, Hoekstra O, Lammertsma AA. On the use of image derived input functions in oncological FDG PET studies. Eur J Nucl Med 1999; 26:1489-1492.
39. 18F-FDG PET scans. J Nucl Med 2001; 42:1622-1629.
40. 68Ga]EDTA and positron computed tomography. J Cereb Blood Flow Metab 1984; 4:507-515.
41. Akaike H. A new look at the statistical identification. IEEE Trans Automat Contr 1978; 19:716-723.
42. Schwarz G. Estimating the dimension of a model. Ann Statist 1978; 6:461-464.
43. 18F]-2-fluoro-2-deoxy-Dglucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 2000; 27: 731-743.
44. Goldstein, H. Multilevel statistical models. London: Edward Arnold, 1995.
45. Kim CK, Gupta NC, Chandramouli B, Alavi A. Standardized uptake values of FDG: body surface area correction is preferable to body weight correction. J Nucl Med 1994; 35:164-167.
46. Kim CK, Gupta NC. Dependency of standardized uptake values of fluorine-18 fluorodeoxyglucose on body size: comparison of body surface area correction and lean body mass correction. Nucl Med Commun 1996; 17:890-894.
47. Schomburg A, Bender H, Reichel C, et al. Standardized uptake values of fluorine-18 fluorodeoxyglucose: the value of different normalization procedures. Eur J Nucl Med 1996; 23:571-574.
48. Sugawara Y, Zasadny KR, Neuhoff AW, et al. Reevaluation of the standardized uptake value for FDG: variations with body weight and methods for correction. Radiology 1999; 213: 521-525.
49. 18F-FDG PET. J Nucl Med 2002; 43:1304-1309.
50. Avril N, Bense S, Ziegler SI, et al. Breast imaging with fluorine-18-FDG PET: quantitative image analysis. J Nucl Med 1997; 38:1186-1191.
51. 11C]tyrosine PET. J Nucl Med 1997; 38: 692-696.
52. Graham MM, Peterson LM, Hayward RM. Comparison of simplified quantitative analyses of FDG uptake. Nucl Med Biol 2000; 7:647-655.
53. Langen KJ, Braun U, Rota KE, et al. The influence of plasma glucose levels on fluorine-18-fluorodeoxyglucose uptake in bronchial carcinomas. J Nucl Med 1993; 34:355-359.
54. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer - a PET study. J Nucl Med 1993; 34:1-6.
55. Zasadny KR, Wahl RL. Enhanced FDG-PET tumor imaging with correlation-coefficient filtered influx-constant images. J Nucl Med 1996; 37:371-374.
56. Zasadny KR, Wahl RL. Standardized uptake values of normal tissues at PET with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose: variations with body weight and a method for correction. Radiology 1993; 189:847-850.